Day: May 9, 2024

Investor Call Today at 11am ET; Dial-in: 1-844-834-0644 WILMINGTON, Del., May 09, 2024 (GLOBE NEWSWIRE) — Acorn Energy, Inc. (OTCQB: ACFN) (Acorn), a provider of remote monitoring and control solutions for backup power generators, gas pipelines, air compressors and other mission critical assets, announced results for its first quarter ended March 31, 2024 (Q1’24) and will hold an investor call today at 11am ET (see call details below). Summary Financial Results    Q1’24     Q1’23     Change      (dollars in thousands)Monitoring revenue   $ 1,102     $ 1,024         +7.6 %Hardware revenue     1,030       725         +42.1 %Total revenue*   $ 2,132     $ 1,749         +21.9 %Gross profit Margin     74.6 %     75.2 %        Net income (loss) attributable to Acorn stockholders   $ 65     $ (85 )       +$150                           Net...

Total First Quarter Revenue of $25.0 millionillumin Self-Service Revenue up 282% YoY (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, May 09, 2024 (GLOBE NEWSWIRE) — illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 HighlightsFirst quarter 2024 revenue was $25.0 million, a decrease of 5.8% year-over-year, reflecting a decline in managed service and programmatic revenues – specifically in economically challenged markets within Latin America. illumin self-serve revenue was $8.4 million in the quarter, or 33.6% of total revenue, and was up 282% versus...

– Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 – – Conference Call Today at 8:30 a.m. ET – ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) — Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including fibromyalgia (“FM”) and Long-COVID (“LC”), today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update. Key HighlightsThe BHC-202 3-arm study comparing two dose levels of the valacyclovir/celecoxib combination vs placebo over 12 weeks to treat symptoms of LC is being conducted by the Bateman Horne Center...

Reiterating Revenue Growth throughout the Year MIGDAL HAEMEK, Israel, May 09, 2024 (GLOBE NEWSWIRE) — Tower Semiconductor (NASDAQ: TSEM & TASE: TSEM) reports today its results for the first quarter ended March 31, 2024. First Quarter of 2024 Results Overview Revenue for the first quarter of 2024 was $327 million as compared to $352 million for the fourth quarter of 2023. Revenue for the first quarter of 2023 was $356 million. Gross profit for the first quarter of 2024 was $73 million as compared to $84 million for the fourth quarter of 2023. Gross profit for the first quarter of 2023 was $96 million. Operating profit for the first quarter of 2024 was $34 million, as compared to $45 million in the fourth quarter of 2023. Operating profit for the first quarter of 2023 was $89 million and included $32 million restructuring income,...

– Full Year 2024 Sales Increase 8% to a Record $1.05 Billion ––38% Growth in E-Mobility Drives 17% Year-over-Year Increase in Full Year 2024 Automotive Sales – MANCHESTER, N.H., May 09, 2024 (GLOBE NEWSWIRE) — Allegro MicroSystems, Inc. (“Allegro” or the “Company”) (Nasdaq:ALGM), a global leader in power and sensing semiconductor solutions for motion control and energy efficient systems, today announced financial results for its fourth quarter and full year ended March 29, 2024. “Continued strong momentum in e-Mobility drove record fiscal year 2024 sales to more than $1 billion and record non-GAAP earnings per share of $1.35. We also achieved a record level of design wins of more than $1 billion. I would like to thank the entire Allegro team for their contributions which enabled us to achieve these significant milestones,” said...

Initiated MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101-RIT Phase 1 Clinical Trial Targeted for Launch as Early as Q4 2024 or Q1 2025 WILMETTE, Ill., May 09, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, today announced first quarter 2024 financial results and summarized recent developments. Recent Developments The radiopharma space has had numerous positive recent developments and announcements, from acquisitions to clinical data to reimbursement rates to commercial demand. Since this past December alone, four significant acquisitions have been publicly announced or completed which have had upfront payments ranging from approximately $1 billion to over...

Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim readout of combined data set of LX2006 at multiple doses anticipated in mid-2024; Lexeo expects to provide analysis of natural history data and baseline characteristics of these study participants in advance of interim readout Phase 1/2 clinical trial of LX2020 (HEROIC-PKP2) currently recruiting patients; data update from Cohort 1 on track for 2H 2024 NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq: LXEO),...

MINNEAPOLIS, May 09, 2024 (GLOBE NEWSWIRE) — Tile Shop Holdings, Inc. (Nasdaq: TTSH) (the “Company”), a specialty retailer of natural stone, man-made and luxury vinyl tiles today announced results for its first quarter ended March 31, 2024. First Quarter 2024 Summary Net Sales Decreased 10.1%Comparable Store Sales Decreased 10.2% Gross Margin of 65.8%Net Income of $1.7 Million and Adjusted EBITDA of $7.4 MillionDiluted Earnings per Share of $0.04Cash Provided by Operating Activities of $18.6 MillionEnding Cash Balance of $24.0 Million and No Long-Term Debt Management Commentary – Cabell Lolmaugh, CEO “Continued softness in existing home sales contributed to lower levels of traffic in our stores and had an adverse impact on our comparable store sales during the first quarter of 2024. Despite these challenges, we saw an improvement...

Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2024, and provided a business update. “As the obesity therapeutics space evolves, increasing attention is being placed on agents that are able to drive weight loss while addressing the quality of that weight loss and the comorbidities of obesity. With significant weight loss, preservation of lean mass and reductions in serum lipids and liver...

Income and EBITDA Growth Highlight Performance GARDEN CITY, N.Y., May 09, 2024 (GLOBE NEWSWIRE) — Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of branded consumer products used in the home, today reported its financial results for the quarter ended March 31, 2024. Rob Kay, Lifetime’s Chief Executive Officer, commented, “We are pleased with our performance in the first quarter as we delivered results that were both in line with our expectations and above the broader market. While shipments for the quarter were under pressure as a result of both economic headwinds and inventory rationalization efforts among select retailers, our sell-through rates remained strong, a testament to the strength of our product offerings across channels. Further, we were able to expand our...